Q-omics provides the consensus-scored SH3D21 profile across patient tissues and cancer cell-line models. SH3D21 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SH3D21 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SH3D21 RNA expression shows 19,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where SH3D21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3D21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3D21 survival associations across molecular data types. SH3D21 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3D21 RNA expression–survival associations across cancer types. High SH3D21 expression shows unfavorable associations in KICH, LIHC, LGG, MESO and KIRC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SH3D21 RNA expression.
This table summarizes SH3D21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SH3D21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3D21 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, BLCA, HNSC and LUAD. The KIRC box plot shows higher SH3D21 RNA expression in tumor versus normal tissue (log2 FC = +0.938, t-test p < 0.001).
This table shows molecular features associated with SH3D21 in patient tissues and cancer cell lines. In patient samples, SH3D21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3D21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
